CD274 and neoplasm: In summary, myeloid cells have been investigated as predictive markers of response to anti-PD-L1 treatment only in few studies, comprising different tumor types and a variety of myeloid subsets, hindering up to now the definition of biomarkers clearly correlated to patient response.